127 related articles for article (PubMed ID: 33841639)
21. The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients' age.
Wu Y; Xu J; Xu J; Wang Y; Wang L; Lv W; Hu J
Biomark Res; 2020; 8():9. PubMed ID: 32308981
[TBL] [Abstract][Full Text] [Related]
22. Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.
Jessurun CAC; Vos JAM; Limpens J; Luiten RM
Front Oncol; 2017; 7():233. PubMed ID: 29034210
[TBL] [Abstract][Full Text] [Related]
23. Gene Expressions and High Lymphocyte Count May Predict Durable Clinical Benefits in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
Mouritzen MT; Ladekarl M; Hager H; Mattesen TB; Lippert JB; Frank MS; Nøhr AK; Egendal IB; Carus A
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760450
[TBL] [Abstract][Full Text] [Related]
24. Association of
Jia M; Yao L; Yang Q; Chi T
Front Oncol; 2020; 10():168. PubMed ID: 32154170
[TBL] [Abstract][Full Text] [Related]
25. MiRNA expression patterns are associated with tumor mutational burden in lung adenocarcinoma.
Lv Y; Huang Z; Lin Y; Fang Y; Chen Z; Pan L; Zhang Y; Xu Z
Oncoimmunology; 2019; 8(10):e1629260. PubMed ID: 31646073
[No Abstract] [Full Text] [Related]
26. Development and Validation of a 12-Gene Immune Relevant Prognostic Signature for Lung Adenocarcinoma Through Machine Learning Strategies.
Xue L; Bi G; Zhan C; Zhang Y; Yuan Y; Fan H
Front Oncol; 2020; 10():835. PubMed ID: 32537435
[No Abstract] [Full Text] [Related]
27. An enhanced genetic mutation-based model for predicting the efficacy of immune checkpoint inhibitors in patients with melanoma.
Pan C; Tang H; Wang W; Wu D; Luo H; Xu L; Lin XJ
Front Oncol; 2022; 12():1077477. PubMed ID: 36733353
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma.
Domblides C; Leroy K; Monnet I; Mazières J; Barlesi F; Gounant V; Baldacci S; Mennecier B; Toffart AC; Audigier-Valette C; Doucet L; Giroux-Leprieur E; Guisier F; Ricordel C; Molinier O; Perol M; Pichon E; Robinet G; Templement-Grangerat D; Ruppert AM; Rabbe N; Antoine M; Wislez M
J Thorac Oncol; 2020 May; 15(5):860-866. PubMed ID: 31991225
[TBL] [Abstract][Full Text] [Related]
29. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
30. Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer.
Greally M; Chou JF; Chatila WK; Margolis M; Capanu M; Hechtman JF; Tuvy Y; Kundra R; Daian F; Ladanyi M; Kelsen DP; Ilson DH; Berger MF; Tang LH; Solit DB; Diaz LA; Schultz N; Janjigian YY; Ku GY
Clin Cancer Res; 2019 Oct; 25(20):6160-6169. PubMed ID: 31337644
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer.
Fang W; Ma Y; Yin JC; Hong S; Zhou H; Wang A; Wang F; Bao H; Wu X; Yang Y; Huang Y; Zhao H; Shao YW; Zhang L
Clin Cancer Res; 2019 Aug; 25(16):5015-5026. PubMed ID: 31085721
[TBL] [Abstract][Full Text] [Related]
32. Higher Tumor Mutation Burden and Higher PD-L1 Activity Predicts the Efficacy of Immune Checkpoint Inhibitor Treatment in a Patient With Four Lung Cancers. A Case Report.
Usuda K; Niida Y; Iwai S; Funasaki A; Sekimura A; Motono N; Yamada S; Uramoto H
Front Oncol; 2020; 10():689. PubMed ID: 32582526
[TBL] [Abstract][Full Text] [Related]
33. Somatic mutations in genes associated with mismatch repair predict survival in patients with metastatic cancer receiving immune checkpoint inhibitors.
Liu Y; Chen L; Zhang S; Shu Y; Qi Q; Zhu M; Peng Y; Ling Y
Oncol Lett; 2020 Oct; 20(4):27. PubMed ID: 32774500
[TBL] [Abstract][Full Text] [Related]
34. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
[TBL] [Abstract][Full Text] [Related]
35. Impaired Cytolytic Activity and Loss of Clonal Neoantigens in Elderly Patients With Lung Adenocarcinoma.
Gong Z; Jia Q; Chen J; Diao X; Gao J; Wang X; Zhu B
J Thorac Oncol; 2019 May; 14(5):857-866. PubMed ID: 30768970
[TBL] [Abstract][Full Text] [Related]
36. Potential Predictive Value of
Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL
Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262
[No Abstract] [Full Text] [Related]
37. Fusing WGCNA and Machine Learning for Immune-Related Gene Prognostic Index in Lung Adenocarcinoma: Precision Prognosis, Tumor Microenvironment Profiling, and Biomarker Discovery.
He J; Luan T; Zhao G; Yang Y
J Inflamm Res; 2023; 16():5309-5326. PubMed ID: 38026246
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with
Oya Y; Kuroda H; Nakada T; Takahashi Y; Sakakura N; Hida T
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32283823
[TBL] [Abstract][Full Text] [Related]
39. Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy.
Wang Q; Li M; Yang M; Yang Y; Song F; Zhang W; Li X; Chen K
Aging (Albany NY); 2020 Feb; 12(4):3312-3339. PubMed ID: 32091408
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice.
Campesato LF; Barroso-Sousa R; Jimenez L; Correa BR; Sabbaga J; Hoff PM; Reis LF; Galante PA; Camargo AA
Oncotarget; 2015 Oct; 6(33):34221-7. PubMed ID: 26439694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
